Fig. 4

Risk of progression of albuminuria for patients with T2DM in different categories of baseline BMI and initial BW loss associated with SGLT2i treatment. Compared with patients with normal BMI (18.5–22.9 kg/m²), those with obesity II (BMI: ≥ 35.0 kg/m²) was associated with a higher risk of progression of albuminuria [new-onset microalbuminuria (urine albumin to creatinine ratio (ACR) > 30 mg/g) or macroalbuminuria (ACR > 300 mg/g)] after multivariate adjustment (A). Compared with those with no BW loss following SGLT2i treatment, BW loss of 0.0–2.4%, 2.5–4.9%, 5.0–7.5%, and 7.5–9.9% following SGLT2i treatment were all associated with a significantly lower risk of progression of albuminuria after multivariate adjustment (B). Adjusted risk factors of outcome as shown in Fig. 3. The abbreviations as in Fig. 1 to 3.